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ABSTRACT 
Genetic association studies provide evidence for a substantial polygenic component to 
schizophrenia, although the neurobiological mechanisms underlying the disorder remain largely 
undefined. Building on recent studies supporting a role for developmentally regulated 
epigenetic variation in the molecular etiology of schizophrenia, this study aimed to identify 
epigenetic variation associated with both a diagnosis of schizophrenia and elevated polygenic 
risk burden for the disease across multiple brain regions. Genome-wide DNA methylation was 
quantified in 262 post-mortem brain samples, representing tissue from four brain regions 
(prefrontal cortex, striatum, hippocampus and cerebellum) from 41 schizophrenia patients and 
47 controls. We identified multiple disease-associated and polygenic risk score-associated 
differentially methylated positions and regions, which are not enriched in genomic regions 
identified in genetic studies of schizophrenia and do not reflect direct genetic effects on DNA 
methylation. Our study represents the first analysis of epigenetic variation associated with 
schizophrenia across multiple brain regions and highlights the utility of polygenic risk scores for 
identifying molecular pathways associated with etiological variation in complex disease. 
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INTRODUCTION 
Schizophrenia is a severe neurodevelopmental disorder, characterized by episodic psychosis and 
altered cognitive function(1), that contributes significantly to the global burden of disease(2). 
Twin and family studies have highlighted a notable heritable component to schizophrenia(3), 
however the role of genetic variation in the etiology of the disorder is complex. Rare, highly 
penetrant inherited and de novo mutations have been implicated in some cases of 
schizophrenia(4-7), however, susceptibility is predominantly attributed to the action of common 
genetic variants of low penetrance. Recently, a large-scale genome-wide association study 
(GWAS) identified 108 independent genomic loci exhibiting genome-wide significant 
association with schizophrenia, which provided convincing evidence for a substantial polygenic 
component to etiology within signals falling below genome-wide levels of significance(8). 
Despite these advances in understanding the genetic epidemiology of schizophrenia, little is 
known about the mechanisms by which schizophrenia risk variants mediate disease 
susceptibility in the brain(9, 10).  
 
Improved understanding about the biology of the genome has led to increased interest in the role 
of non-DNA sequence-based variation in the etiology of neurodevelopmental phenotypes, 
including schizophrenia. Epigenetic processes have been hypothesized to mediate associations 
between genetic risk burden, environmental risk exposure and phenotype. Furthermore, a 
growing number of studies provide evidence for the dysregulation of epigenetic mechanisms in 
complex psychiatric disorders(9, 11-13). To date, such studies have primarily focused on DNA 
methylation at CpG dinucleotides, as this is the best characterized and most stable epigenetic 
modification. DNA methylation influences gene expression via physical disruption of 
transcription factor binding and through attraction of methyl-binding proteins that initiate 
chromatin compaction and gene silencing. Of note, previous studies characterizing 
schizophrenia-associated methylomic variation have been limited by small sample number or 
the assessment of a single brain region(14-19).  
 
 at U
niversity of Exeter on January 3, 2017
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
 4
This study represents the first attempt to systematically examine the association of genome-
wide methylomic variation with schizophrenia and schizophrenia polygenic risk burden, across 
multiple brain regions, using post-mortem tissue obtained from two independent cohorts of 
schizophrenia patients and controls.   
 
RESULTS 
Overview of experimental strategy 
We quantified genome-wide patterns of DNA methylation in 262 post-mortem samples derived 
from four brain regions dissected from 88 individuals (41 schizophrenia and 47 non-psychiatric 
controls) obtained from two independent brain banks, using the Illumina Infinium 
HumanMethylation450 BeadChip (450K array) (Illumina Inc., San Diego, CA, USA) (see 
Materials and Methods). In total, data from 76 prefrontal cortex (PFC; n = 38 schizophrenia 
patients and 38 controls), 82 striatum (STR; n = 37 schizophrenia patients and 45 controls), 27 
hippocampus (HC; n = 14 schizophrenia patients and 13 controls) and 77 cerebellum (CER; n = 
37 schizophrenia patients and 40 controls) samples passed stringent quality control (QC) 
metrics and were used for analysis (Table 1 and Supplementary Figure 1). For post-mortem 
brain regions available from both brain banks (PFC, STR and CER), a meta-analysis approach 
was used to combine data from both sources. Our initial analyses focused on identifying 
differentially methylated positions (DMPs) and differentially methylated regions (DMRs) 
associated with disease status. Analyses were first performed independently for each brain 
region, and we subsequently employed a multi-level model to identify consistent DNA 
methylation markers of schizophrenia present across multiple brain regions. We subsequently 
calculated a schizophrenia polygenic risk score (PRS) for Caucasian samples (Supplementary 
Table 1) to identify DMPs and DMRs associated with polygenic risk burden. A schematic 
overview of the study is given in Supplementary Figure 2 with more detailed experimental 
procedures described in the Material and Methods section. 
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Methylomic differences between schizophrenia cases and controls – differentially methylated 
positions and regions 
No global differences in DNA methylation - estimated by averaging across all probes on the 
array included in our analysis - were identified between schizophrenia patients and controls in 
any of the four brain regions (PFC: schizophrenia (SZ) = 48.43%, controls (CTR) = 48.57%, = 
0.51; STR: SZ = 49.20%, CTR = 49.16%, P = 0.12; HC: SZ = 48.44%, CTR = 48.38%, P = 
0.05; CER: SZ = 47.25%, CTR = 47.27%, P = 0.89). Furthermore, the estimated “DNA 
methylation age” for each sample – calculated using an epigenetic clock based on DNA 
methylation values (20, 21) – was strongly correlated with actual chronological age in each 
brain region (PFC: ρ= 0.94, P < 2.20E-16; STR: ρ = 0.93, P < 2.20E-16; HC: ρ = 0.94, P = 
1.30E-13; CER: ρ = 0.86, P = 2.20E-16) (Supplementary Figure 3), with no evidence for 
accelerated “epigenetic aging” in affected individuals (PFC: P = 0.16, STR: P = 0.73, HC: P = 
0.73, CER: P = 0.30). Taken together, these data indicate that schizophrenia is not associated 
with any systemic methylomic differences across the probes included on the Illumina 450K 
array in the brain regions tested in this study. 
 
In contrast, we find significant evidence for schizophrenia-associated variation at specific loci 
across the genome in each brain region. Our first analyses focused on identifying DNA 
methylation differences between schizophrenia cases and non-psychiatric controls. The fifty 
top-ranked schizophrenia-associated DMPs in each brain region are listed in Supplementary 
Tables 2-5 and Supplementary Figures 4-7, with 12 DMPs passing a highly stringent 
significance threshold (P < 1.66E-07, see Materials & Methods) (Table 2, Figure 1 and 
Supplementary Figure 8). Results for all probes included in the final QC’d dataset can be 
downloaded from http://epigenetics.essex.ac.uk/schizobrain/. Although the specific list of top-
ranked DMPs identified in each tissue is relatively distinct, many DMPs are characterized by 
consistent effects across brain regions (Supplementary Figures 4-7), and for DMPs identified 
in each of the four individual brain regions, schizophrenia-associated DNA methylation 
differences are significantly positively correlated with those at the same probes in the other 
three brain regions (correlations for: PFC DMPs = 0.43 (STR), 0.31 (HC), 0.61 (CER); STR 
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SMPs = 0.77 (PFC), 0.65 (HC), 0.74 (CER); HC DMPs = 0.63 (PFC), 0.74 (HC), 0.54 (CER); 
and CER DMPs = 0.64 (PFC), 0.36 (STR), 0.46 (HC)) (Supplementary Figure 9). 
 
Quantile-quantile (Q-Q) plots for the P-values of the analyses in each tissue are shown in 
Supplementary Figure 10A-D highlighting some evidence of P-value inflation (PFC λ = 1.18, 
STR λ = 1.02, HC λ = 1.13, CER λ = 1.23) in several of the brain regions; such inflation is not 
unusual in epigenome-wide association study (EWAS) analyses and standard genomic control 
methods – widely used in GWAS – are not suitable for EWAS data (26). Because it is likely 
that unmeasured factors beyond the variables included in our analysis model (i.e. age, sex, and 
estimated neuronal proportion) confound our case-control analysis of methylomic variation 
associated with schizophrenia, we therefore investigated the impact of additional surrogate 
variables capturing variation in DNA methylation on the association statistics for schizophrenia-
associated DMPs. We compared the regression coefficients from our initial analysis model to 
sequential models iteratively including up to 10 principal components (PCs) derived from the 
DNA methylation data, observing a strong positive correlation for schizophrenia-associated 
DNA methylation differences between analyses (Supplementary Figures 11-14). This 
sensitivity analysis implies that although additional confounders potentially exist in our dataset, 
the identified schizophrenia-associated DMPs are relatively robust to the major PCs associated 
with methylomic variance.  
 
We next used comb-p(27) (see Materials and Methods) to identify spatially correlated regions 
of differential DNA methylation significantly associated with schizophrenia (Šidák-corrected P 
< 0.05, number of consecutive probes ≥ 2) in each of the four brain regions (PFC: 13 DMRs 
spanning an average of 7 probes and 279bp; STR: 2 DMRs spanning an average of 8 probes and 
328bp; HC: 1 DMRs spanning an average of 7 probes and 260bp; CER: 10 DMRs spanning an 
average of 5 probes and 246bp)  (Figure 2 and Table 3). Many DMRs are again characterized 
by consistent schizophrenia-associated differences in DNA methylation across multiple brain 
regions (Figure 2). Of note, a DMR spanning four probes within the RPH3AL gene on 
chromosome 17, which encodes a protein that plays a direct regulatory role in calcium-ion-
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dependent exocytosis, is consistently hypomethylated in schizophrenia patients across all four 
brain regions (PFC: median DNA methylation difference = -8.03%, median P = 8.27E-04; STR: 
median DNA methylation difference = -5.32%, median P = 7.14E-03; HC: median DNA 
methylation difference = -7.84%, median P = 1.78E-02; CER: median DNA methylation 
difference = -10.24, median P = 3.86E-03) (Figure2 and Supplementary Figures 15-16). We 
subsequently confirmed schizophrenia-associated hypomethylation across the same region using 
Bumphunter  (32) - an alternative DMR analysis approach – in the PFC (P = 4.85E-05), STR (P 
= 2.00E-04) and CER (P = 6.01E-06). To validate the differences identified across this DMR 
using the Illumina 450K array we employed bisulfite-pyrosequencing to quantify DNA 
methylation across an amplicon spanning three CpG sites (including cg11940040 and two 
adjacent CpG sites not on the 450K array) in the PFC (n = 35 schizophrenia and 36 controls) 
and STR (n = 36 schizophrenia and 41 controls) samples. All three sites were significantly 
hypomethylated in schizophrenic patients compared to controls in both brain regions 
(Supplementary Table 6 and Supplementary Figures 15-16), with DNA methylation 
differences reflecting those identified using the 450K array (PFC: average DNA methylation 
difference = -8.68%, P = 1.72E-03; STR: average DNA methylation difference = -5.33%, P = 
1.41E-02).  
 
Consistent methylomic markers of schizophrenia across brain regions 
We next employed a multi-level model to further explore consistent schizophrenia-associated 
differences across multiple brain regions (see Material and Methods). As reported in previous 
analyses of epigenetic variation in the human brain (33-35), our data show that at a global level 
the patterns of DNA methylation in the CER are very distinct to the other three brain regions 
included in this study (Supplementary Figure 17); for this reason we excluded the CER from 
our multi-region model and focused on identifying consistent signals across the PFC, STR and 
HC. Of note, there is inflation in the distribution of P-values in the multi-region case-control 
analysis (λ = 1.43, Supplementary Figure 9E); although our model is designed to control for 
the non-independence of brain regions from the same individual, it is possible that combining 
datasets has resulted in some residual inflation. Compared to other published EWAS analyses, 
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however, this inflation is relatively modest and we do not identify an excessively large number 
of DMPs passing our stringent family-wise significance threshold. Supplementary Table 7 and 
Supplementary Figure 18 lists the fifty top-ranked cross-region DMPs, with significant cross-
region DMRs listed in Supplementary Table 8 and Supplementary Figure 19; in total we 
identified 22 DMRs spanning an average of 6 probes and 317bp. The multi-region model DMPs 
provide further support for several loci identified in our previous study of schizophrenia 
prefrontal cortex (17) including GSDMD (cg26173173: P = 4.28E-05), RASA3 (cg24803255: P 
= 1.51E-04), PPFIA1 (cg08171022: P = 1.19E-02) and MYT1L (cg00236305: P = 4.62E-04) 
(Supplementary Table 9), suggesting that DNA methylation differences at these loci are 
consistently-associated with schizophrenia across the three regions. Of note, the top-ranked 
cross-region DMRs include a highly-significant signal spanning 11 CpG sites (Šidák-corrected 
P = 8.90E-11) annotated to WNT5A(36), in addition to regions annotated several loci identified 
in the analyses of the different brain regions such as GBP4 (Šidák-corrected P = 0.01), PRDM9 
(Šidák-corrected P = 0.04) and RPH3AL (Šidák-corrected P = 1.23E-05).  
 
Methylomic variation associated with schizophrenia polygenic risk score (PRS) 
A recent large-scale GWAS of schizophrenia identified 128 independent associations spanning 
108 genomic regions in a meta-analysis of over 80,000 samples(8). 5006, 5058, 5066 and 4951 
Illumina 450K array probes included in our PFC, STR, HC and CER analyses, respectively, are 
located within these broad genomic regions. Although a number of probes within these regions 
were nominally associated with schizophrenia (see Supplementary Table 10 for all DMPs with 
P < 1.00E-03), we found no overall enrichment of DMPs in any of the analyses performed 
(Fisher’s exact test: PFC P = 0.20, STR P = 0.27, HC P = 0.59, CER P = 0.55, multi-region 
model P =0.04) at a Bonferroni corrected P-value for the number of tests performed (P < 
1.25x10-2). 
 
Beyond the specific genome-wide significant loci identified in GWAS, an individual’s 
accumulated genetic burden can be quantified to define an overall PRS – i.e. the sum of trait-
associated alleles across many genetic loci, weighted by effect sizes estimated by GWAS 
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analyses (8, 37). We next explored if an increased burden of polygenic variants associated with 
schizophrenia was itself associated with variation in DNA methylation in the brain. Each 
sample was genotyped and SNP data was imputed using the latest data release from the 1,000 
Genomes project, and a PRS for each sample was generated using data from the recent 
schizophrenia GWAS(8) (see Materials and Methods). None of the samples used in this study 
were included in the PGC GWAS analysis of schizophrenia, and thus did not contribute to 
defining the variants included in the PRS. To avoid population stratification effects, ethnicity 
was determined using data from HapMap Phase 3 (see Materials and Methods) and non-
Caucasian samples (n = 10) were excluded from subsequent PRS-based analyses. Despite the 
relatively small sample size (see Supplementary Table 1 for an overview of samples), 
schizophrenia patients (n = 34) were characterized by a significantly higher PRS than controls 
(n = 40) (P = 4.42E-03) (Figure 3A). For Caucasian samples, we repeated our case-control 
study with and without the inclusion of PRS as a covariate. For the top-ranked DMPs associated 
with schizophrenia (presented above), there was a highly-significant correlation of both 
schizophrenia-associated DNA methylation difference and P-value across all four brain regions 
(correlations ranging from 0.80 to 1.00 for all comparisons, except for the HC (0.56-1.00)), 
indicating that polygenic risk burden is not impacting greatly on the schizophrenia-associated 
differences identified.  
 
We next employed a linear model, controlling for age, sex, and neuronal estimates (except in the 
CER, as described in Materials and Methods) to identify methylomic variation associated with 
the schizophrenia PRS. Q-Q plots for the P-values of the analyses in each tissue are shown in 
Supplementary Figure 20, again providing evidence of some P-value inflation (PFC λ = 0.96, 
STR λ = 1.10, HC λ = 1.17, CER λ = 1.26) in some brain regions. The 15 PRS-associated DMPs 
passing our stringent significance threshold listed in Table 4 and the fifty top-ranked PRS-
associated DMPs in each brain region presented in Supplementary Figures 21-24 and 
Supplementary Tables 11-14. Results for all probes included in the analysis of PRS can be 
downloaded from http://epigenetics.essex.ac.uk/schizobrain/. The top-ranked PRS-associated 
DMP is cg20640266 (annotated to the zinc-finger gene ZNF618), at which an increased 
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polygenic burden was associated with elevated DNA methylation in the CER (P = 6.50E-7) 
(Figure 3B). Although the specific top-ranked PRS-associated loci in each tissue are distinct, 
effect sizes at PRS-associated DMPs are significantly correlated across brain regions 
(Supplementary Table 15 and Supplementary Figure 25), with the exception of the HC 
where the low number of samples (n = 23) means we are probably underpowered to detect 
robust effects. Furthermore, although there is no direct overlap between the top-ranked 
schizophrenia-associated and PRS-associated DMPs, the effect sizes at the top-ranked PRS-
associated probes are significantly correlated with those at the same sites in the case-control 
analysis, and vice versa, across all brain regions (Supplementary Figures 26-29). We used 
identified spatially correlated regions of differential DNA methylation significantly associated 
with polygenic burden for schizophrenia (Šidák-corrected P < 0.05, number of consecutive 
probes ≥ 2). PRS-associated DMRs in each of the four brain regions are listed in Table 5 and 
Figure 4 (PFC: 6 DMRs spanning an average of 6 probes and 291bp; STR: 4 DMRs spanning 
an average of 5 probes and 237bp; CER: 10 DMRs spanning an average of 6 probes and 340bp; 
no DMRs were identified in the HC).  
 
We next employed a multi-level model to identify consistent PRS-associated DMPs 
(Supplementary Figure 30 and Supplementary Table 16) and DMRs (Supplementary 
Figure 31 and Supplementary Table 17 across PFC, STR and HC. Of note, the top-ranked 
PRS-associated DMP (cg04910228), at which PRS is negatively correlated with DNA 
methylation (estimate = -0.38%, P = 6.50E-07), is located within the TSNAX-DISC1 locus on 
chromosome 1 (Figure 3C). A balanced translocation involving this gene that segregates with 
several major psychiatric disorders including schizophrenia has been intensively studied in a 
Scottish pedigree(5), although the involvement of this locus in the etiology of the disorder 
remains controversial and common genetic variation in this region was not identified in recent 
GWAS analyses(40, 41). Our data suggest that an increased polygenic burden for schizophrenia 
may impact upon regulatory variation of the DISC1 locus in the brain.  
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Polygenic risk score-associated methylomic variation does not reflect direct genetic effects on 
DNA methylation 
Although one of the top-ranked PRS-associated DMPs was located within a GWAS-nominated 
genomic region - cg01682070 (annotated to TAOK2 on chromosome 16), at which DNA 
methylation was positively correlated with PRS (P = 4.30E-08) - we found no significant 
enrichment of PRS-associated DMPs within GWAS-nominated schizophrenia-associated 
regions (Fisher’s exact test: PFC P = 0.83, STR P = 0.53, HC P = 0.24, CER P = 0.53). We 
next characterized methylation quantitative trait loci (mQTLs) associated with the 99,904 
variants included in the PRS calculation, using linkage disequilibrium (LD)-pruned independent 
SNPs and a genome-wide mQTL significance threshold of P < 3.69E-13, as described in 
Hannon et al., 2016(34). Given the low number of samples from the HC, mQTL analyses were 
not performed for this brain region. In total we identified 255 associations between genetic 
variants and DNA methylation sites in the PFC, representing 198 unique SNPs (Supplementary 
Table 18), with 247 mQTL pairs (representing 201 independent SNPs) identified in the STR 
(Supplementary Table 19) and 282 mQTL pairs (representing 219 independent SNPs) 
identified in the CER (Supplementary Table 20). None of the top-ranked PRS-associated 
DMPs in any of the individual brain regions, in addition to those identified in the multi-region 
model, were significantly associated with any of the genetic variants included in the PRS 
calculation. Because it is possible that weaker-effect mQTLs may still underlie some of the 
PRS-associated epigenetic variation, we subsequently relaxed our mQTL significance threshold 
to P < 1.00E-10, again finding no overlap with PRS-associated DMPs (Supplementary Figure 
32). Together, these data indicate that PRS-associated epigenetic variation does not directly 
result from genetic influences on DNA methylation in any of the brain regions tested.
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DISCUSSION 
In this study we quantified genome-wide patterns of DNA methylation in postmortem brain 
samples isolated from PFC, STR, HC and CER obtained from two independent cohorts of 
schizophrenia patients and controls. We identified numerous DMPs and DMRs associated with 
disease and polygenic risk burden; many of these loci were differentially methylated in 
individual brain regions although others showed consistent patterns across brain regions. Many 
of the DMPs and DMRs associated with increased genetic burden for schizophrenia are 
independent of the changes observed in the disease itself, and there is no evidence for direct 
genetic effects on DNA methylation (i.e. via mQTLs) for variants included in the PRS. Overall, 
our study represents the first analysis of epigenetic variation associated with schizophrenia 
across multiple brain regions and highlights that DNA methylation in the brain is robustly 
associated with the polygenic risk burden, independently of many of the changes observed in 
the disease itself.  
 
Genes annotated to several of the schizophrenia-associated DMPs and DMRs have been 
previously implicated in the pathophysiology of schizophrenia or have relevant roles in brain 
function; such as NCAM1 (which encodes a neural cell adhesion molecule with a well-
established role in neurodevelopment and synaptic plasticity)(22, 23), SYNPO (which encodes a 
actin-associated protein that is associated with postsynaptic densities and dendritic spines and 
differentially expressed in schizophrenia brain)(24), GBP4 (that encodes a gene that has been 
found to be differentially expressed in schizophrenia patients)(25), PRDM9 (which encodes a 
protein with histone H3K4 trimethyltransferase activity during meiosis that has been previously 
hypothesized to play a role in schizophrenia)(28, 29) and WNT5A (an important 
neurodevelopmental locus)(36).  Of note, a DMR spanning four probes within the RPH3AL 
gene (which encodes a protein that plays a direct regulatory role in calcium-ion-dependent 
exocytosis), was consistently hypomethylated in schizophrenia patients across all four brain 
regions. Interestingly, this DMR is also functionally annotated to the DOC2B gene using the 
Genomic Regions Enrichment of Annotation Tool (GREAT) (30); this encodes a high-affinity 
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Ca2+ sensor involved in spontaneous neurotransmitter release from synaptic vesicles (31). Most 
notably, the top-ranked probe associated with PRS in our multi-region model (i.e. across PFC, 
STR and HC) is located in the gene body of DISC1, a gene previously strongly linked to 
schizophrenia in a Scottish pedigree with a balanced translocation spanning the locus(5). Our 
data suggest that an increased PRS for schizophrenia may impact upon regulatory variation of 
the DISC1 locus in the brain, implicating a potentially common pathway between polygenic and 
highly penetrant single locus etiologies that warrants further investigation.  
 
Despite this being the first study to quantify DNA methylation across four different brain 
regions from schizophrenia patients and controls, this study has a number of important 
limitations. First, the number of samples assessed in this study is relatively low, especially for 
analyses involving the HC, which was only available from one of the two brain-bank cohorts. 
Despite this, we were able to identify a number of DMPs and DMRs passing our stringent 
significance thresholds in both the analyses of diagnosed schizophrenia and polygenic risk 
burden. Furthermore, although the magnitude of change at the differentially methylated loci was 
relatively small (i.e. involving a relative small proportion of cells in a given brain region), we 
were able to technically validate the Illumina 450K array data using bisulfite-pyrosequencing. 
Of note, given the relatively small number of individual donors, the PRS analyses were 
undertaken in both cases and controls, and therefore our study design is potentially confounded 
in a way that makes it not completely independent from the schizophrenia analysis. Despite this, 
we observed no direct overlap between the top-ranked schizophrenia-associated and PRS-
associated DMPs although effect sizes were correlated. 
 
Second, because epigenetic processes play an important role in defining cell-type-specific 
patterns of gene expression(42-44), the use of bulk tissue from each brain region is a potential 
confounder in DNA methylation studies(45, 46). Despite our efforts to control for the effect of 
cell type diversity in DNA methylation quantification in our analyses using in silico approaches, 
this approach is not suitable to estimate the neuronal proportion in the cerebellum and cannot 
inform us about disease relevant DNA methylation changes specific to individual brain cell 
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types. Third, there is increasing awareness of the importance of 5-hydroxymethyl cytosine (5-
hmC) in the human brain(47, 48), although this modification cannot be distinguished from DNA 
methylation using standard bisulfite-based approaches(49). It is therefore plausible that many of 
the differences identified in this study are confounded by modifications other than DNA 
methylation. To date, no study has evaluated the role of 5-hmC in schizophrenia or any other 
psychiatric disorder, although a recent paper from our group quantified levels of 5-hmC across 
the genome in human cortex and cerebellum (49); of note, none of the significant DMPs 
identified in this study were characterized by detectable levels of this DNA modification.  
  
Definitively distinguishing cause from effect in epigenetic epidemiology is difficult, especially 
for disorders like schizophrenia that manifest in inaccessible tissues such as the brain and are 
therefore particularly refractory to longitudinal study(46). However, our observation of 
consistent changes across multiple brain regions in two independent cohorts for many DMPs 
and DMRs suggests that the identified loci are potentially directly relevant to the schizophrenia 
pathogenesis. Furthermore, our identification of PRS-associated variation in DNA methylation 
potentially less confounded by medication intake and other disease-associated exposures that 
can influence case-control analyses. We tested if the PRS associations reflected the direct 
effects of genetic variation by testing whether the genetic variants used to derive the polygenic 
risk scores are mQTLs that influence DNA methylation at PRS-associated DMPs; our analyses 
suggest that the associations with schizophrenia polygenic burden are independent from genetic 
variation itself.  
 
Unlike for GWAS, little work has been done to determine appropriate levels of significance in 
EWAS and a major issue in the field of epigenetic epidemiology is that no empirically-derived 
thresholds have been established that can be used consistently across studies (Mill & Heijmans, 
Nature Reviews Genetics, 2014). To establish a stringent multiple-testing significance threshold 
to identify schizophrenia-associated DMPs, we utilized data from a large Illumina 450K dataset 
(n = 675 individuals) generated as part of recent study from our group (50). Briefly, we 
performed 5,000 EWAS permutations using a multiple linear regression model controlling for 
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age, sex, smoking and cell composition, and used these to estimate the nominal P-value for 5% 
family-wise error (P = 1.66E-07). Although we believe this approach to be highly stringent, 
providing a significance threshold that can be used in subsequent EWAS analyses, it is 
important to note that the permutations were performed in an independent dataset.  
 
Although we controlled for age, sex and derived neuronal composition in our analyses, it is 
plausible that other factors may be confounding our case-control analyses of schizophrenia, as 
highlighted by the inflated Q-Q plots observed for several of the analyses. For example, 
epidemiological data highlights a much higher rate of smoking in schizophrenia patients 
compared to unaffected controls(51, 52). Although smoking has been shown to have striking 
effects on DNA methylation in blood(53), none of the robust smoking-associated DMPs 
identified in blood are amongst the schizophrenia DMPs identified in any of the four brain 
regions assessed in the current study. Although P-value inflation is a common feature of many 
DNA methylation datasets, standard genomic control methods – widely used in GWAS – are 
not suitable for EWAS data (26)). Therefore, we investigated the impact of including additional 
surrogate variables capturing variation in DNA methylation on the association statistics for 
schizophrenia-associated DMPs (Supplementary Figures 11-14), observing that the identified 
schizophrenia-associated DMPs are relatively robust to the major PCs associated with 
methylomic variance. Of course, the modest P-value inflation observed in this study does not 
necessarily result from residual confounding; it is plausible that there are multiple differentially 
methylated loci of small effect associated with schizophrenia, and that changes across genomic 
regions are coordinated. Finally, although the control samples used in this study were selected 
to be free of psychiatric morbidity, little additional information about these donors is available; 
given the nature of post-mortem tissue, for example, they will have died from a number of 
different causes. Although our study presents novel evidence for associations between 
schizophrenia diagnosis, schizophrenia polygenic burden and variable DNA methylation across 
different brain regions, further replication using larger sample sizes is essential to further 
support these results. Future studies should focus on understanding the transcriptional 
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consequences of the observed associations, and testing whether these associations are causal or 
a consequence of disease and/or medication.  
 
In summary, our data provide evidence for differences in DNA methylation across multiple 
brain regions in schizophrenia. We also identify evidence for differential DNA methylation 
associated with increased polygenic burden for schizophrenia, including in the vicinity of 
DISC1, a gene previously implicated in the disease by a highly penetrant balanced translocation. 
Of note, there is no enrichment of loci identified in a recent large GWAS of schizophrenia 
amongst DMPs for either schizophrenia or schizophrenia PRS identified in this study. Our study 
represents the first analysis of epigenetic variation associated with schizophrenia across multiple 
brain regions and highlights the utility of polygenic risk scores for identifying molecular 
pathways associated with etiological variation. 
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MATERIALS AND METHODS 
Post-mortem tissue samples 
Post-mortem PFC (Brodmann area 9), STR (putamen), HC, and CER samples from a total of 41 
schizophrenia patients and 47 non-psychiatric control samples were obtained from the MRC 
London Neurodegenerative Diseases Brain Bank (LNDBB) 
(http://www.kcl.ac.uk/ioppn/depts/bcn/Our-research/Neurodegeneration/brain-bank.aspx) and 
the Douglas-Bell Canada Brain Bank (DBCBB), Montreal (http://douglasbrainbank.ca/). 
LNDBB subjects were approached in life for written consent for brain banking, and all tissue 
donations were collected and stored following legal and ethical guidelines (NHS reference 
number 08/MRE09/38; LBBND brain bank HTA license number 12293). Schizophrenia 
patients were diagnosed by trained psychiatrists according to Diagnostic and Statistical Manual 
of Mental Disorders criteria. DBCBB samples were collected post-mortem following consent 
obtained with next of kin, according to tissue banking practices regulated by the Quebec Health 
Research Fund (http://ethique.msss.gouv.qc.ca/), and based on the OECD Guidelines on Human 
Biobanks and Genetic Research Databases 
(http://www.oecd.org/science/biotech/44054609.pdf). Psychiatric diagnoses were based on best-
estimate diagnostic procedures, following SCID I diagnostic interviews conducted with 
informants, as described elsewhere(54). The current study was approved by the University of 
Exeter Medical School Research Ethics Committee (reference number 13/02/009). All samples 
were dissected by trained neuropathologists from each brain bank, snap-frozen and stored at -
80°C.  
 
Methylomic profiling 
Genomic DNA was isolated using a standard phenol-chloroform extraction protocol and 
assessed for quality and purity using spectrophotometry. DNA (~500 ng) from each sample was 
treated with sodium bisulfite using the EZ-96 Gold DNA methylation kit (Zymo Research, 
Irvine, CA, USA). DNA methylation was quantified using the Illumina Infinium 
HumanMethylation450 BeadChip (Illumina, San Diego, CA, USA) scanned on an Illumina 
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HiScan System (Illumina, San Diego, CA, USA). Samples were batched by tissue and brain-
bank, and randomized with respect to diagnosis, sex and age throughout all experimental 
procedures. Illumina Genome Studio software was used to extract the raw signal intensities of 
each probe (without background correction or normalization). QC and normalization steps were 
performed separately for samples from each brain bank. Signal intensities for each probe were 
imported into R(55) using the methylumi and minfi packages(56, 57). Multidimensional scaling 
plots of sex chromosome probes were used to check that the predicted sex corresponded with 
the reported sex for each individual. The ten bisulfite conversion control probes on the array 
were used to calculate the efficiency of the bisulfite conversion reaction. Comparison of 65 SNP 
probes on the array confirmed that matched tissues were sourced from the same individual. The 
65 SNP probes, probes on sex chromosomes, cross-hybridizing probes(58, 59) and probes 
containing a SNP with minor allele frequency > 5% within 10 bp of the single base extension 
position were excluded from analysis(58). The ‘pfilter’ function of the wateRmelon package(60) 
was used to filter data by beadcount and detection P-value. Samples with > 1% probes with a 
detection P-value > 0.01 were removed, along with probes with a detection P-value > 0.05 in at 
least 1% of samples and/or a beadcount < 3 in 5% of samples were also removed. The ‘dasen’ 
function in wateRmelon was used to normalize the data as previously described(60). The total 
number of CpG sites included and excluded for each brain region in the final dataset are 
presented in Supplementary Table 21. In total 5 PFC, 4 STR, 3 HC and 4 CER samples were 
excluded during these stringent QC procedures. The number of samples in the final dataset used 
in the analyses are presented in Table 1. 
 
Genotyping and derivation of schizophrenia polygenic risk scores  
Genomic DNA (200 ng) from each individual was used for genotyping on the Illumina Infinium 
HTS HumanOmniExpress-24 BeadChip v1-0 using an iScan Microarray Scanner (Illumina, San 
Diego, CA, USA), according to manufacturer’s instructions. Illumina GenomeStudio software 
was used for genotype calling and the data were exported as .ped and .map files. PLINK(61) 
was used to remove samples with > 5% missing data and SNPs with > 1% missing values, 
Hardy-Weinberg equilibrium P < 1.00E-03 or minor allele frequency of < 5%. Sample ethnicity 
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was determined by merging the genotypes with data from HapMap Phase 3 
(http://www.sanger.ac.uk/resources/downloads/human/hapmap3.html) and LD pruning the 
overlapping SNPs such that no pair of SNPs within 1500 bp had r2 > 0.20. GCTA software(62) 
was used to calculate principal components of the genetic data, which were visually inspected to 
ascertain ethnicity for each sample by comparison with the known ethnicities of the HapMap 
sample. Non-Caucasian samples (n = 10) were excluded from PRS analyses. For imputation, 
genotypes were recoded into .vcf files using PLINK1.9(63) and VCFtools(64) before uploading 
to the Michigan Imputation Server 
(https://imputationserver.sph.umich.edu/start.html#!pages/home), which uses SHAPEIT(65) to 
phase haplotypes, and Minimac3(66) with the most recent 1000 Genomes reference panel 
(phase 3, version 5) (http://www.1000genomes.org/). PRSs were calculated in PLINK(61) using 
the imputation dosages from 99940 variants and the score file downloaded from the Psychiatric 
Genomics Consortium (PGC) website (https://www.med.unc.edu/pgc/downloads) where 
GWAS results have been clumped, retaining the best association (identified by P-value) in each 
LD block. 
 
Identification of schizophrenia-associated differentially methylated positions and regions  
An overview of the samples included in our schizophrenia case-control analysis is given in 
Table 1. We estimated the proportion of neuronal cells for each sample using the CETS 
package in R(45). To identify DMPs in each brain region we used linear regression with the 
preprocessed and normalized methylation (β) values separately for samples from each brain 
bank using disease status, age, sex and neuronal proportion estimates as independent variables. 
Given the nature of the samples used in this study, information about medication, smoking 
status and other phenotypic information was not available and could not be included as 
covariates in analyses. Neuronal proportion estimates were not included as a variable for 
cerebellum samples because of the high proportion of non-NeuN-expressing neurons, which 
make CETS unsuitable for estimating cell composition. In our data, cerebellum neuronal 
estimates derived from CETS correlated significantly with age (ρ = 0.48, P = 1.26E-05) 
reflecting the previously reported age-associated variance in the ratio of NeuN-expressing and 
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non-expressing cells in the cerebellum(45). For tissues collected from both brain banks (PFC, 
STR and CER) a fixed-effect meta-analysis on the adjusted mean β values computed with 
inverse variance weights was performed using the ‘metacont’ from the meta package in R(67). 
Only probes that survived QC and were common to both datasets were used in the meta-analysis 
(Supplementary Table 21). We employed a fixed-effects (rather than random-effects) meta-
analysis because with only two sample cohorts contributing to the pooled effect size, the 
precision of the estimate of the between-studies variance is poor using a random-effects model. 
To identify DMRs, we identified spatially correlated P-values in our data using the Python 
module comb-p(27) to group spatially correlated DMPs (seed P-value < 1.00E-03, minimum of 
2 probes) at a maximum distance of 300 bp in each brain tissue. DMR P-values were corrected 
for multiple testing using Šidák correction(68) which corrects the combined P for na/nr tests, 
where na is the total number of probes tested in the initial EWAS and nr the number of probes in 
the given region. The Bioconductor package Bumphunter (32) was used to confirm specific 
DMRs identified by comb-p with an alternative method. The probes common to the PFC, STR 
and HC analyses (411,449 probes) were tested for homogeneous DNA methylation effects 
associated with schizophrenia across the three brain regions using a mixed-effects model with 
sex, age, neuronal estimates and brain bank as fixed effects and individual and brain region as 
random effects. 
 
Identification of polygenic risk score-associated differentially methylated positions and regions  
Although the utility of PRS for exploring the molecular genomic mechanisms involved in 
disease pathogenesis is largely unexplored, PRS-associated epigenetic variation is potentially 
less affected by factors associated with the disease itself (e.g. medication exposure, stress, and 
smoking), which can confound case-control analyses. An overview of the samples included in 
our analysis of methylomic variation associated with polygenic burden for schizophrenia is 
given in Supplementary Table 1. To identify PRS-associated DMPs we performed a multiple 
linear regression for each cohort using the PRS, age, sex and neuronal proportion estimates as 
independent variables (except in the CER, where neuronal proportion estimates were not 
included, as described above). For each of the tissues collected from both brain banks (PFC, 
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STR and CER), a fixed-effect meta-analysis based on the linear regression estimates and their 
standard errors was computed with inverse variance weights using the ‘metagen’ function from 
the meta package in R(67). Only probes that passed our QC metrics and were common to both 
cohorts in each brain region were used in the meta-analysis (Supplementary Table 21). To 
identify PRS-associated DMRs we used comb-p(27) as described above. To identify 
homogeneous DNA methylation effects associated with PRS across PFC, STR and HC data a 
mixed effects model was fitted as described above. 
 
Establishing multiple testing significance threshold for EWAS analysis 
To establish a stringent multiple-testing significance threshold to identify schizophrenia-
associated DMPs, we utilized data from a large Illumina 450K dataset (n = 675 individuals) 
generated as part of recent study from our group (50). The sample was randomly split into cases 
and controls 5,000 times, and for each permutation an EWAS was performed using a multiple 
linear regression model controlling for age, sex, smoking and cell composition, and the probe-
level P-values recorded. The minimum or most significant P-value was identified for each 
permutation and the 5th percentile across the permutations was used to estimate the nominal P-
value for 5% family-wise error (P = 1.66E-07). 
 
Targeted validation using bisulfite-pyrosequencing 
Bisulfite-pyrosequencing was used to quantify DNA methylation across the chr17:154410-
154672 region identified in our DMR analysis. The bisulfite-pyrosequencing assay was 
designed using the PyroMark Assay design software (Qiagen, Hilden, Germany), with bisulfite-
PCR amplification performed in duplicate using the primers and assay conditions in 
Supplementary Table 22. Fully methylated control samples were included in all experiments. 
DNA methylation was quantified across amplicons using the Pyromark Q24 system (Qiagen) 
following the manufacturer's standard instructions and Pyromark Q24 CpG 2.0.6 software.  
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FIGURE LEGENDS 
Figure 1. Forest plots showing the top-ranked schizophrenia-associated differentially 
methylated positions (DMPs). Shown are data for 12 DMPs associated with schizophrenia at a 
highly stringent significance threshold (P < 1.66E-07) derived using permutations to estimate 
the nominal P-value for 5% family-wise error. Additional information on these DMPs is given 
in Table 2. Color depicts brain region in which the schizophrenia-association was identified: 
prefrontal cortex = blue, striatum = green, hippocampus = red, and cerebellum = yellow. 
 
Figure 2. Differentially methylated regions (DMRs) associated with schizophrenia. Shown 
in chromosomal order are DMRs (Šidák-corrected P < 0.05, number of probes ≥ 2) associated 
with schizophrenia identified in any of the four tissues. Effect sizes for individual probes within 
each DMR are also shown for the other three brain regions (blue = hypomethylation, red = 
hypermethylation). Further details for individual DMRs are provided in Table 3. 
 
Figure 3. Increased polygenic burden for schizophrenia is associated with altered DNA 
methylation. A) Schizophrenia samples included in our study scored significantly higher on a 
polygenic risk score derived from a recent large collaborative GWAS of schizophrenia. B) The 
top-ranked PRS-associated DMP was cg20640266 (annotated to ZNF618) in the cerebellum. C) 
The top-ranked multi-region PRS-associated DMP was cg04910228 (annotated to the TSNAX-
DISC1 locus). 
 
Figure 4. Differentially methylated regions (DMRs) associated with schizophrenia 
polygenic risk score (PRS). Shown in chromosomal order are DMRs (Šidák-corrected P < 
0.05, number of probes ≥ 2) associated with schizophrenia PRS identified in any of the four 
brain regions. Effect sizes for individual probes within each DMR are also shown for the other 
three brain regions (blue = hypomethylation, red = hypermethylation). Further details for 
individual DMRs are provided in Table 5.
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Table 1: Overview of samples included in the schizophrenia case versus control analysis. LNDBB = MRC London Neurodegenerative Diseases Brain Bank, 
DBCBB = Douglas-Bell Canada Brain Bank. 
 
   
N Sex (male:female) Age at death  Brain weight (g) pH 
LNDBB 
Prefrontal cortex 
schizophrenia 20 11:9 62.05 ± 15.87 1232.94 ± 129.22 6.64 ± 0.28 
controls 23 17:6 62.04 ± 18.74 1368.48 ± 185.22 6.49 ± 0.33 
total 43 28:15 62.05 ± 17.26 1310.88 ± 175.52 6.56 ± 0.31 
P - - 1.00 0.01 0.13 
Striatum 
schizophrenia 21 11:10 61.76 ± 16.61 1227.44 ± 123.68 6.60 ± 0.30 
controls 28 20:8 63.43 ± 18.16 1360.52 ± 184.59 6.46 ± 0.33 
total 49 31:18 62.71 ± 17.36 1302.10 ± 172.37 6.53 ± 0.32 
P - - 0.74 0.01 0.17 
Hippocampus 
schizophrenia 14 10:4 60.71 ± 15.93 1271.25 ± 139.22 6.63 ± 0.28 
controls 13 11:2 61.92 ± 17.80 1415.27 ± 173.82 6.48 ± 0.41 
total 27 21:6 61.30 ± 16.54 1340.13 ± 169.81 6.56 ± 0.34 
P - - 0.85 0.04 0.31 
Cerebellum 
schizophrenia 21 11:10 61.76 ± 16.61 1227.44 ± 123.68 6.60 ± 0.30 
controls 23 17:6 61.39 ± 19.25 1361.30 ± 185.03 6.46 ± 0.33 
total 44 28:16 61.57 ± 17.83 1232.41 ± 172.79 6.60 ± 0.32 
P - - 0.95 0.01 0.15 
DBCBB 
Prefrontal cortex 
schizophrenia 18 15:3 45.50 ± 16.61 1431.78 ± 188.16 6.23 ± 0.22 
controls 15 13:2 42.27 ± 14.80 1462.96 ± 175.17 6.12 ± 0.32 
total 33 28:5 44.03 ± 15.65 1447.37 ± 179.32 6.18 ± 0.27 
P - - 0.56 0.64 0.27 
Striatum 
schizophrenia 16 13:3 46.25 ± 17.10 1410.90 ± 193.35 6.21 ± 0.22 
controls 17 14:3 45.65 ± 16.82 1438.02 ± 180.91 6.09 ± 0.31 
total 33 27:6 45.94 ± 16.69 1426.27 ± 183.61 6.15 ± 0.27 
P - - 0.92 0.70 0.23 
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Cerebellum 
schizophrenia 16 14:2 44.56 ± 15.84 1404.62 ± 161.90 6.25 ± 0.22 
controls 17 14:3 45.65 ± 16.82 1438.02 ± 180.91 6.09 ± 0.31 
total 33 28:5 45.12 ± 16.10 1422.94 ± 170.58 6.17 ± 0.28 
P - - 0.85 0.59 0.10 
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Table 2. Top-ranked schizophrenia-associated differentially methylated positions (DMPs). Shown are DMPs associated with schizophrenia at a highly stringent 
significance threshold (P < 1.66E-07) derived using permutations to estimate the nominal P-value for 5% family-wise error. Top-ranked schizophrenia-associated 
DMPs for each of the four brain regions profiled are presented in Supplementary Tables 2-5. Illumina and Genomic Regions Enrichment of Annotation Tool 
(GREAT)(30) annotation is listed for each DMP. LNDBB = London Neurodegenerative Disorders Brain Bank; DBCBB = Douglas-Bell Canada Brain Bank. Note 
hippocampus tissue was not available from the DBCBB.  
Probe ID 
Genomic position 
(hg19) 
Illumina gene 
annotation 
Genic region 
GREAT 
annotation(30) 
Brain region 
DNA methylation 
difference (%) 
P 
DNA 
methylation 
difference 
(%) LNDBB 
P-value 
LNDBB 
DNA 
methylation 
difference 
(%) DBCBB 
P-value 
DBCBB 
cg08743050 chr11:113113936 NCAM1 Body TTC12; NCAM1 
Prefrontal 
cortex 
-3.80 1.84E-08 -1.80 0.15 -4.63 8.39E-09 
cg14609448 chr21:34896882 GART Body; 3'UTR 
DNAJC28; 
GART  
Cerebellum 2.29 2.48E-08 1.37 0.02 3.11 3.60E-08 
cg08103144 chr5:150028986 SYNPO Body MYOZ3; SYNPO Striatum -3.17 3.64E-08 0.08 0.94 -4.43 6.61E-11 
cg03847432 chr7:43391524 HECW1 Body 
STK17A; 
HECW1  
Striatum 2.71 5.23E-08 1.55 0.04 3.69 4.76E-08 
cg22182016 chr15:57998894 
GRINL1A; 
GCOM1 
TSS200; Body POLR2M  Striatum -0.51 5.67E-08 -0.27 0.14 -0.59 5.41E-08 
cg01757160 chr12:96588951 ELK3 5'UTR ELK3  Cerebellum 0.57 5.74E-08 0.58 5.13E-04 0.56 3.04e-05 
cg25361651 chr20:29847402 DEFB115 Body 
DEFB115; 
DEFB116  
Striatum 4.43 6.52E-08 2.27 0.10 5.63 3.67E-08 
cg22221320 chr1:89664340 GBP4 Body GBP4  Striatum 6.93 7.88E-08 2.39 0.23 10.24 1.58E-09 
cg07751266 chr16:67515323 ATP6V0D1 TSS1500 ATP6V0D1  Hippocampus -1.35 1.27E-07 -1.35 1.27E-07 - - 
cg09757430 chr13:28397122 - - PDX1; GSX1  Cerebellum -3.13 1.37E-07 -2.38 0.02 -3.54 1.65E-06 
cg05686445 chr7:127636396 
C7orf54; 
SND1 
TSS1500; 
Body 
LRRC4; SND1  
Prefrontal 
cortex 
-3.65 1.63E-07 -2.04 0.07 -4.67 1.57E-07 
cg20751795 chr19:58281019 ZNF586 TSS200 ZNF586  Cerebellum 0.57 1.64E-07 0. 42 1.17E-06 0.13 0.03 
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Table 3: Significant schizophrenia-associated differentially methylated regions (DMRs). Shown in chromosomal order is the location of significant (Šidák-
corrected P < 0.05) DMRs identified in each of the four brain regions, with the median P-value for DMR probes given for the other three brain regions (bold denotes 
median P < 0.05 and grey boxes denote regions that were not identified in that brain region). The ‘Gene’ column lists the combined Illumina and Genomic Regions 
Enrichment of Annotation Tool (GREAT) annotation(30). 
Region Gene(s) Probes N 
probes 
Prefrontal cortex Striatum Hippocampus Cerebellum 
Median P Šidák P Median P Šidák P Median P Šidák P Median P Šidák P 
chr1:25257505-25257814 RUNX3 
cg07996594; cg04221877; cg15014975; cg24019564; 
cg10993442; cg24842859; cg20695936; cg13106389; 
cg18087266; cg25882256; cg04250451; cg10013501 
12 1.22E-02 1.02E-02 0.36   0.66   0.29   
chr1:89664260-89664583 GBP4 
cg23978657; cg02482460; cg22221320; cg21365602; 
cg20410995; cg14563196 
6 8.36E-03   5.36E-04 3.16E-12 0.93   7.06E-02   
chr1:160336475-160336713 NHLH1 
cg18023842; cg08247612; cg13992678; cg00006397; 
cg00881010 
5 0.24   0.62   0.42   8.00E-04 1.64E-05 
chr1:175162044-175162398 
KIAA0040; TNN; 
TNR 
cg11908570; cg22626041; cg26563583; cg17839543; 
cg18880390; cg00099768; cg13857382; cg11973900; 
cg08873628; cg00321850 
10 2.34E-02 7.62E-04 0.47   0.25   0.25   
chr2:241936844-241937035 SNED1 cg16937168; cg03785076; cg21304158 3 0.45   0.74   0.89   5.16E-05 6.68E-05 
chr4:1202653-1202967 
LOC100130872-
SPON2; CTBP1 
cg14527262; cg04228083; cg17227257; cg16721321; 
cg26130533; cg14505741; cg11104416; cg18085660; 
cg11888738; cg01638225; cg21082272 
11 3.61E-02 1.32E-02 0.41   0.66   0.72   
chr4:2627014-2627247 
FAM193A; TNIP2; 
RNF4 
cg25790133; cg05083414; cg05949640; cg22980079; 
cg14549256; cg20163033; cg00097088 
7 7.22E-03 2.93E-02 0.56   0.94   0.44   
chr5:23506738-23507031 
PRDM9 
cg04362002; cg10589310 2 5.91E-02   3.76E-02   0.11   4.69E-06 3.65E-05 
chr5:23507450-23507657 
cg22054885; cg19837938; cg02444433; cg25472530; 
cg22079902; cg01667892 
6 0.10   0.11   0.45   5.33E-04 5.49E-08 
chr6:30853948-30854234 DDR1 
cg16215084; cg25251478; cg26321999; cg00934322; 
cg07187855; cg24566261; cg09965419; cg17091577 
8 2.28E-02 7.87E-03 0.75   0.73   0.21   
chr7:5535463-5535935 
MIR589; TNRC18; 
FBXL18 
cg01942816; cg22108567; cg25343388; cg09286367; 
cg17419731; cg01024247; cg00966405; cg04155485 
8 5.48E-03 3.44E-03 0.55   0.36   0.54   
chr8:145728203-145728631 GPT 
cg16587265; cg14476479; cg23793500; cg00280345; 
cg16582889; cg07658280; cg26572973; cg05241828; 
cg09957864; cg25600446; cg06110286; cg19352605 
12 1.80E-03 5.53E-09 0.49   0.74   0.51   
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chr10:124638756-124639111 
FAM24B; 
LOC399815 
cg03804621; cg16299003; cg11218091; cg14708218; 
cg18195080; cg15252215 
6 1.05E-02   4.88E-03   0.47   5.15E-03 4.71E-04 
chr10:131264786-131265074 MGMT 
cg26950715; cg02330106; cg12575438; cg02022136; 
cg23998405; cg01341123; cg25946389 
7 0.13   0.54   0.83   1.01E-02 7.35E-03 
chr11:192897-193063 
ODF3; SCGB1C1; 
LOC653486 
cg18793661; cg22280333; cg03960562; cg02378673; 
cg20297976 
5 0.26   0.62   0.25   4.55E-04 2.08E-05 
chr11:34460298-34460558 CAT 
cg20731136; cg06027906; cg07768201; cg03720043; 
cg02109652; cg06908474; cg01847719 
7 0.36   3.61E-02   1.00E-02 9.44E-04 0.21   
chr12:125145446-125145642 NCOR2; SCARB1 cg12077664; cg27645498; cg19888509 3 2.00E-03 2.20E-02 0.56   0.59   0.18   
chr12:131452238-131452298 SFSWAP; GPR133 cg24336338; cg03776878; cg23617848 3 0.80   0.23   0.59   1.20E-04 2.50E-03 
chr13:114202683-114202862 TFDP1; TMCO3 cg16567723; cg24121069; cg11312353 3 6.38E-04 1.94E-02 0.12   0.74   9.18E-03   
chr16:2892518-2892913 
PRSS30P; 
TMPRSS8 
cg07645761; cg00491180; cg01006802; cg27137258; 
cg10448227; cg10186456 
6 7.18E-03 5.65E-03 3.91E-02   0.12   4.27E-03 1.62E-04 
chr17:154410-154672 DOC2B; RPH3AL cg08770870; cg11940040; cg10440639; cg23246911 4 8.27E-04 1.02E-04 7.14E-03   1.78E-02   3.86E-03 3.44E-02 
chr19:19639970-19640076 YJEFN3 cg11244672; cg20098710 2 3.00E-04 4.49E-02 0.43   0.50   0.54   
chr19:57742112-57742445 AURKC 
cg25802888; cg19568003; cg18644286; cg26332114; 
cg19603903; cg23371413; cg06643849; cg25432232; 
cg22711741 
9 0.23   1.34E-02 2.64E-03 0.86   0.27   
chr21:46898048-46898138 
COL18A1; 
SLC19A1 
cg03208198; cg20383948 2 1.30E-04 2.31E-02 0.68   0.49   0.14   
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Table 4: Top-ranked differentially methylated positions (DMPs) associated with schizophrenia polygenic score (PRS). Shown are DMPs associated with the 
schizophrenia PRS at a highly stringent significance threshold (P < 1.66E-07) derived using permutations to estimate the nominal P-value for 5% family-wise error. 
Top-ranked PRS-associated DMPs for each of the four brain regions profiled are presented in Supplementary Tables 12-15. The methylation difference is 
measured per PRS unit. Illumina and Genomic Regions Enrichment of Annotation Tool (GREAT)(30) annotation is listed for each DMP. LNDBB = London 
Neurodegenerative Disorders Brain Bank; DBCBB = Douglas-Bell Canada Brain Bank. 
Probe ID 
Genomic 
position (hg19) 
Illumina gene 
annotation 
Gene region 
GREAT 
annotation(30) 
Brain 
region 
DNA 
methylation 
change (%) 
P 
DNA 
methylation 
change (%) 
LNDBB 
P-value 
LNDBB 
DNA 
methylation 
change (%) 
DBCBB 
P-value 
DBCBB 
cg18847009 chr2:70175826 - - ASPRV1; MXD1  
Prefrontal 
cortex 
-0.51 8.98E-08 -0.50 7.14E-07 -0.66 0.03 
cg26893445 chr15:85924187 AKAP13 5'UTR AKAP13  Striatum 0.15 6.73E-08 0.16 6.80E-08 0.03 0.21 
cg12595281 chr15:93633172 RGMA TSS1500 RGMA  Striatum 0.68 6.85E-08 0.82 5.36E-10 0.13 0.07 
cg20640266 chr9:116811789 ZNF618 Body AMBP; ZNF618  Cerebellum 0.60 1.62E-09 0.74 2.06E-06 0.32 0.02 
cg27150552 chr7:48026856 SUNC1 3'UTR HUS1; SUN3  Cerebellum 0.34 1.30E-08 0.36 6.44E-09 0.09 0.68 
cg05209768 chr2:164573665 FIGN Body KCNH7; FIGN  Cerebellum 0.70 1.55E-08 0.70 1.31E-07 0.70 0.04 
cg07793808 chr12:122019006 KDM2B 
TSS200; 
TSS1500 
KDM2B  Cerebellum -0.19 1.66E-08 -0.21 2.94E-04 -0.17 1.28E-05 
cg10218777 chr3:133180261 BFSP2 Body CDV3; BFSP2  Cerebellum 0.67 3.86E-08 0.65 4.24E-07 0.86 0.03 
cg01682070 chr16:29996774 TAOK2 Body HIRIP3; TAOK2  Cerebellum 0.32 4.20E-08 0.37 1.21E-08 0.11 0.38 
cg11786558 chr17:2266589 SGSM2 Body SGSM2; MNT  Cerebellum 0.69 4.35E-08 0.84 1.23E-06 0.52 4.73E-03 
cg26053083 chr11:14995770 - - CALCA  Cerebellum -0.15 4.41E-08 -0.15 2.53E-06 -0.14 4.95E-03 
cg01022840 chr14:71250264 MAP3K9 Body MAP3K9; TTC9  Cerebellum 0.63 7.86E-08 0.66 7.10E-07 0.53 0.04 
cg08478539 chr15:68640339 ITGA11 Body FEM1B; ITGA11  Cerebellum 0.69 1.06E-07 0.80 3.06E-07 0.45 0.06 
cg23788334 chr2:137181176 - - THSD7B; CXCR4  Cerebellum -0.13 1.15E-07 -0.15 1.45E-05 -0.11 1.56E-03 
cg16904520 chr2:230590962 - - DNER; TRIP12  Cerebellum 0.26 1.25E-07 0.27 2.06E-06 0.22 0.02 
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Table 5: Differentially methylated regions (DMRs) significantly associated with polygenic score (PRS) for schizophrenia. Shown in chromosomal order is the 
location of significant (Šidák-corrected P < 0.05) DMRs identified in each of the four brain regions, with the median P-value for DMR probes given for the other 
three brain (bold denotes median P < 0.05 and grey boxes denote regions that were not identified in that brain region). The ‘gene’ column lists the combined 
Illumina and Genomic Regions Enrichment of Annotation Tool (GREAT) annotation (30). 
Region Gene Probes N 
probes 
Prefrontal cortex Cerebellum Striatum Hippocampus 
Median P Šidák P Median P Šidák P Median P Šidák P Median P Šidák P 
chr1:84326547-84326857 TTLL7 
cg08882038; cg07807165; cg02531516; cg18116902; 
cg26347197; cg24955204; cg02483449 
7 0.40 
 
0.05 0.03 0.68 
 
0.11   
chr1:168356537-168356674 TBX19; XCL2  cg22695117; cg20678082; cg10555800; cg06122518 4 0.02 0.02 0.13 
 
0.39 
 
0.14   
chr2:3486706-3487165 ADI1; TRAPPC12 cg14053828; cg15541040; cg15506890; cg08493051 4 0.03 
 
2.82E-03 3.63E-04 0.03 
 
0.84   
chr2:97405651-97405880 LMAN2L 
cg13915892; cg04771938; cg17340948; cg17526658; 
cg12930819; cg04918358; cg15007626 
7 0.66 
 
5.73E-03 9.07E-03 0.59 
 
0.57   
chr4:74847646-74848017 PF4 
cg15158783; cg21043213; cg16072462; cg15398841; 
cg02530824; cg06834998; cg05509609; cg13126871 
8 3.39E-03 2.10E-05 0.16 
 
0.03 
 
0.02   
chr5:102898463-102898730 NUDT12 cg02976617; cg13665998; cg09166085; cg07655627 4 2.27E-03 0.01 0.08 
 
3.91E-03 
 
0.31   
chr5:493262-493614 
SLC9A3; EXOC3 
cg19107578; cg25518170; cg20402284; cg25346936 4 0.76 
 
1.17E-03 3.87E-04 0.67 
 
0.72   
chr5:497397-497640 cg22985016; cg16555556; cg14533753; cg00190355 4 0.49 
 
5.41E-03 0.05 0.17 
 
0.82   
chr6:30042919-30043419 RNF39 
cg12704854; cg11562284; cg02552311; cg03219282; 
cg24766429; cg23500724; cg10865856; cg24016627; 
cg23939808; cg12967914; cg00853042; cg23027574; 
cg05853632; cg22105332; cg19006429; cg27532187; 
cg01631162 
17 0.06 2.99E-04 0.40 
 
0.41 
 
0.23   
chr6:33084549-33084841 HLA-DPB2; COL11A2 
cg03943025; cg08693832; cg27264993; cg21870640; 
cg08088295; cg17833071; cg23075555; cg13524302; 
cg02662362; cg24465429; cg24266485 
11 0.03 0.04 0.11 
 
0.19 
 
0.23   
chr11:2907670-2907755 CDKN1C cg05090695; cg11744767; cg05559445; cg23225147 4 1.08E-03 1.93E-04 0.08 
 
0.40 
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chr12:75784617-75785098 GLIPR1L2 
cg14292619; cg00108944; cg23588049; cg12351126; 
cg02415057; cg07311024; cg02071292 
7 0.66 
 
1.27E-03 2.49E-07 0.55 
 
0.19   
chr13:51417846-51418222 
DLEU7; RNASEH2B; 
ST13P4  
cg20170533; cg08274637; cg13846270; cg27051129; 
cg10359157; cg20400592; cg05965387; cg17288288; 
cg03389701 
9 0.50 
 
8.88E-03 5.83E-04 0.31 
 
0.28   
chr13:113540400-113540632 ATP11A; MCF2L  cg17842918; cg11462099; cg26666292; cg11520003 4 0.53 
 
0.17 
 
2.57E-03 0.01 0.70   
chr16:66400320-66400600 CDH5 
cg08872742; cg02078525; cg00401972; cg00044665; 
cg16471830; cg22319147 
6 0.68 
 
0.56 
 
6.43E-03 0.02 0.74   
chr19:2650727-2650864 GNG7; GADD45B cg03070741; cg01250212; cg27324541; cg10350536 4 0.43 
 
0.65 
 
3.07E-03 0.04 0.72   
chr19:11784514-11784956 ZNF833 
cg04598224; cg05950877; cg26772540; cg25394203; 
cg21771200; cg15209566; cg02274869 
7 0.44 
 
4.66E-03 1.81E-04 0.09 
 
0.66   
chr19:17357315-17357642 NR2F6 cg06108395; cg20981127; cg16749578; cg24057642 4 0.44 
 
4.68E-04 2.12E-07 0.49 
 
0.13   
chr19:47287964-47288264 SLC1A5; STRN4 
cg02711608; cg25607249; cg21766592; cg12165685; 
cg11645155; cg01406381 
6 0.33 
 
0.51 
 
1.52E-03 7.62E-05 0.64   
chr20:30073399-30073577 
NCRNA00028; HM1; 
REM1 
cg15537254; cg13159946; cg02991085; cg25502144; 
cg21846177 
5 0.17 
 
5.15E-04 2.06E-04 0.06 
 
0.29   
chr20:32308081-32308344 PXMP4 
cg27194921; cg25092328; cg20588982; cg06231372; 
cg12297619; cg24270031 
6 0.02 
 
0.03 
 
0.02 0.03 0.25   
chr22:38071534-38071678 LGALS1 
cg21064451; cg21737444; cg01264106; cg08835221; 
cg27619353; cg19853760 
6 0.65 
 
1.22E-03 2.30E-07 0.62 
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ABBREVIATIONS 
 
PFC Prefrontal cortex 
CER Cerebellum 
STR Striatum 
HC Hippocampus 
PRS Polygenic risk score 
DMP Differentially methylated positon 
DMR Differentially methylated regions 
GWAS Genome-wide association study 
LNDBB MRC London Neurodegenerative Diseases Brain Bank 
DBCBB Douglas-Bell Canada Brain Bank 
EWAS Epigenome-wide association study 
QC Quality control 
GREAT Genomic Regions Enrichment of Annotation Tool 
mQTLs Methylation quantitative trait loci 
MHC Major histocompatibility complex 
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Figure 3. Increased polygenic burden for schizophrenia is associated with altered DNA methylation. A) 
Schizophrenia samples included in our study scored significantly higher on a polygenic risk score derived 
from a recent large collaborative GWAS of schizophrenia. B) The top-ranked PRS-associated DMP was 
cg20640266 (annotated to ZNF618) in the cerebellum. C) The top-ranked multi-region PRS-associated DMP 
was cg04910228 (annotated to the TSNAX-DISC1 locus).  
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